Refractory Malignant Ascites

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Refractory Malignant Ascites trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingNot Applicable

NCT05726747

QOL and Sarcopenia in Patients With Ascites

Clinical data regarding quality of life in patients with refractory ascites is limited and preceded the development of newer questionnaires that may be more rob…

United States70 participantsStarted 2023-05-23

Treatment: Quality of Life surveys

RecruitingPhase 1

NCT05268172

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, usi…

China40 participantsStarted 2022-12-20

Treatment: IFN-γ and CIK cells, Tcm cells or CAR T cells

All recent trials (15 shown)

Active — Not RecruitingNot Applicable

NCT04326946

International Alfapump Cohort Study

This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss…

Germany, Switzerland400 participantsStarted 2018-08-14

Treatment: Alfapump

UnknownPhase 1

NCT05303844

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab for patients with refractory mal…

China25 participantsStarted 2022-04-02

Treatment: H101, Tislelizumab

Refractory Malignant Ascites

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

QOL and Sarcopenia in Patients With Ascites

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

All recent trials (15 shown)

International Alfapump Cohort Study

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

QOL and Sarcopenia in Patients With Ascites

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

All recent trials (15 shown)

International Alfapump Cohort Study

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites

PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology

Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer

ALFApump System Post Marketing Surveillance Registry

Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites

EUS-Guided Drainage of Refractory Malignant Ascites

Trial of Sunitinib for Refractory Malignant Ascites

Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites

Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites